Cytek Biosciences Inc

CTKB

4.320USD

-0.260-5.68%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Cytek Biosciences Inc's Score

Industry at a Glance

Industry Ranking

55 / 208

Overall Ranking

154 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Cytek Biosciences Inc Highlights

StrengthsRisks

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 201.49M.

Overvalued

The company’s latest PE is -8.29, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 80.93M shares, decreasing 0.00% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 11.72K shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

6.000

Target Price

+31.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Cytek Biosciences Inc is 7.42, ranking 73 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 62.14M, representing a year-over-year increase of 8.12%, while its net profit experienced a year-over-year increase of 557.08%.

Score

Industry at a Glance

Previous score

7.42

Change

0



Financials

8.79

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.47

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.87

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.73

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Cytek Biosciences Inc is 8.56, ranking 17 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -8.29, which is -8580.97% below the recent high of 703.39 and -101922.46% above the recent low of -8461.54.

Score

Industry at a Glance

Previous score

8.56

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/208

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Cytek Biosciences Inc is 7.20, ranking 144 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 5.75, with a high of 7.50 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.20

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Cytek Biosciences Inc is 7.06, ranking 37 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 4.73 and the support level at 3.93, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.89

Change

-1.83

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Cytek Biosciences Inc is 7.00, ranking 81 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 70.83%, representing a quarter-over-quarter decrease of 0.20%. The largest institutional shareholder is The Vanguard, holding a total of 7.48M shares, representing 5.82% of shares outstanding, with 23.24% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

15.20M

-1.15%

The Vanguard Group, Inc.

Star Investors

6.93M

-10.40%

Topline Capital Management, LLC

6.94M

+32.75%

HHLR Advisors, Ltd.

6.66M

--

Jiang (Wenbin)

5.36M

+0.79%

Yan (Ming)

6.07M

+0.26%

Millennium Management LLC

3.42M

+269.65%

State Street Investment Management (US)

4.08M

-2.14%

Geode Capital Management, L.L.C.

2.78M

+1.97%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cytek Biosciences Inc is 4.63, ranking 101 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.28. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Cytek Biosciences Inc

CTKB

7.15 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bioventus Inc

BVS

8.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Edwards Lifesciences Corp

EW

8.05 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment